Lantheus Holdings, Inc.

LNTH · XNAS

CIK 1521036fmd_0YBQ1CQ2TEB4NDA9KH19MCRCAVManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	302	331	343	347	339	425	935	1,296	1,534	1,542
Cost of revenue	164	169	168	173	201	238	353	587	546	600
Gross profit	138	162	175	175	139	188	582	710	988	942
Research and development	12	18	17	20	33	45	312	78	168	177
Selling, general and administrative	75	92	93	103	110	219	234	267	372	454
Total operating expenses	–	110	110	123	143	–	–	–	–	–
Impairment of real estate	0	1	0	0	–	–	–	–	–	–
Operating income	57	52	64	52	(4)	(61)	36	365	457	311
Interest expense	27	18	17	14	9	8	7	20	20	20
Interest and investment income	–	0	0	1	0	0	3	20	37	–
Other non-operating income (expense)	0	9	2	(6)	2	(7)	(2)	66	37	31
Income before taxes	28	40	50	29	(11)	(75)	27	411	431	314
Income tax expense	2	(84)	9	(3)	2	(4)	(1)	84	119	80
Net income from continuing operations	27	123	41	32	(13)	(71)	28	327	312	234
Net income	–	123	41	32	(13)	(71)	28	327	312	234
Net income to common shareholders	27	123	41	–	–	(71)	28	327	312	234